Stanford



Tian Yi Zhang, MD, PhD

Assistant Professor of Medicine (Hematology)

Medicine - Hematology

Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Hematology**

  269 Campus Dr Rm 1155

  CCSR Bldg MC 5156

  Stanford, CA 94305

  Tel (650) 726-1484 **Fax** (650) 724-5203

Bio

BIO

Dr. Zhang is a board-certified hematologist. She is also an assistant professor of hematology at Stanford University School of Medicine. In addition to her medical degree, she holds a PhD in cellular and molecular immunology.

In her clinical practice, she treats patients with all forms of hematological malignancies, offering specialized expertise in acute myeloid leukemia, including therapy-resistant cases. For each patient, she develops a personalized care plan encompassing novel treatment options.

Her research activities include conducting early phase clinical trials, investigator initiated clinical trials (IITs), studying the immune repertoire in patients with myeloid malignancies, and exploring cholesterol metabolic dependencies of acute myeloid leukemia (AML).

She was the recipient of an A.P. Giannini Foundation fellowship award, which supports innovative research. The award helped fund Dr. Zhang's study of how AML cells interact with other cells in bone marrow. A significant finding confirmed that AML cells secrete a protein that suppresses the production of red blood cells, the same protein that causes inflammation in disorders such as rheumatoid arthritis and Crohn's disease.

Her many other honors include the National Cancer Institute Career Development (K08) Award, the American Society of Hematology (ASH) Research Training Award for Fellows, Stanford Cancer Institute - American Cancer Society (SCI-ACS) Pilot Grant and Best ASH Abstract Award two years in a row. She also has earned recognition from the National Institutes of Health and American College of Physicians.

She has published her research findings on topics such as advanced therapy for high-risk myelodysplastic syndromes and reversal of bone marrow failure induced by AML. Her work has appeared in Leukemia & Lymphoma, Science Translational Medicine, Cancer Research, the Journal of Clinical Investigation, Journal of Immunology, and elsewhere.

Dr. Zhang is a member of the American Association of Cancer Research and American Society of Hematology. She advises and mentors Stanford medical students, residents and fellows. She delivers invited lectures to faculty and fellows. In addition, she has been an invited speaker on the topic of acute myeloid leukemia at the Association of Northern California Oncologists Update on Hematological Malignancies.

CLINICAL FOCUS

- Hematology

ACADEMIC APPOINTMENTS

- Assistant Professor-Univ Med Line, Medicine - Hematology
- Member, Bio-X

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2025)
- Medical Education: University of Utah School of Medicine (2011) UT
- Fellowship: Stanford University Hematology and Oncology Fellowship (2018) CA
- Residency: University of Utah Internal Medicine Residency (2014) UT
- PhD, University of Utah School of Medicine , Cellular and Molecular Immunology (2007)

LINKS

- The Zhang Lab official website: https://www.thezhanglabstanford.com/

Research & Scholarship

CLINICAL TRIALS

- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS), Recruiting
- A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML), Not Recruiting
- Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation, Not Recruiting
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML, Not Recruiting

Teaching

STANFORD ADVISEES

Med Scholar Project Advisor

Sanjeeth Rajaram, Emily Yang

Postdoctoral Faculty Sponsor

Gabriel Salzman, Alexandre Raphael Wery

Doctoral Dissertation Reader (NonAC)

James Chavez

Publications

PUBLICATIONS

- **Cladribine and low-dose cytarabine as first salvage after hypomethylating agent and venetoclax in acute myeloid leukemia.** *Leukemia research*
  Dutta, R., Schumann, C., Cheung, E., Zhang, T. Y., Ediriwickrema, A., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Mannis, G. N.

2026; 171: 108322

- **Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia.** *Blood cancer discovery*
  Gunaratne, R., Zhou, C. M., Rajaram, S., Tai, J. W., Tanaka, K. L., Tiwari, C., Yang, E. Y., Kim, S., Gao, G., Yin, R., Carleton, M., Alkaitis, M. S., Schwede, et al
  2026

- **A case of true acute eosinophilic leukemia arising from myelodysplastic syndrome.** *Journal of hematopathology*
  Li, Q., Alkaitis, M. S., Shomali, W., Mannis, G. N., Zhang, T. Y., Gotlib, J., Fernandez-Pol, S.
  2026; 19 (1)

- **Novel single cell and bulk NGS assays for improved assessment of MRD (measurable residual disease) and clonal dynamics in acute myeloid leukemia (AML).**
  Zhou, C., Gunaratne, R., Yang, E., Agoglia, R., Jangam, D., Tiwari, C., Tanaka, K., Chiang, T., Ho, C., Lu, S., Zehnder, J. L., Zhang, B., Stehr, et al
  AMER ASSOC CANCER RESEARCH.2026

- **Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.** *Blood*
  Sekrecki, M., Sekrecka, A., Lattupally, R. R., Le, K., Jin, X., Mozes, C., Dwyer, B. G., Zhuang, Z., Romero, B. A., Pineda, J. M., Cao, X., Nguyen, L., Chen, et al
  2026

- **IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease**
  Mustion, G., Castellan, F., Cole, J., Wong, M., Johansson, K., Goldberg, S., Madanat, Y., Chandhok, N., Singh, A., Sallman, D., Churpek, J., Lachowiez, C., Yannucci, et al
  ELSEVIER.2025: 3169-3170

- **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
  Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al
  ELSEVIER.2025: 2525-2526

- **Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia**
  Cho, W., Dutta, R., Cobarrubias, K., Inlow, E., Adre, N., Olson, N., Cunanan, K., Charu, V., Ediriwickrema, A., Zhang, T., Mannis, G.
  ELSEVIER.2025: 8256

- **Sensitive detection of novel structural variants and 3D chromosome conformation reveals likely novel drivers including enhancer hijacking in AML**
  Koehnke, T., Ediriwickrema, A., Bhakta, M., Fortuna, A., Tiwari, C., Sanborn, Z., Zhang, T., Munding, L., Majeti, R.
  ELSEVIER.2025: 5257-5258

- **Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial**
  Bolton, K., Madanat, Y., Chandhok, N., Sallman, D., Singh, A., Vij, K., Churpek, J., Fletcher, L., Schwede, M., Lachowiez, C., Afzal, A., Myhand, R., Velarde, et al
  ELSEVIER.2025: 635-636

- **Inhibition of DOCK1 prevents the clonal expansion of high-risk TP53-mutant clonal hematopoiesis induced by genotoxic stressors**
  Feng, Y., Koehnke, T., Patrick, B., Benard, B., Kayamori, K., Heaton, E., Collins, C., Chavez, J., Zhang, T., Gentles, A., Majeti, R.
  ELSEVIER.2025: 631-632

- **Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16**
  Sekrecki, M., Sekrecka, A., Lattupally, R., Le, K., Cao, X., Chen, V., Zhuang, Z., Dwyer, B., Zhou, C., Tiwari, C., Gabel, A., Kim, W., Stanley, et al
  ELSEVIER.2025: 1474-1475

- **Intra-leukemic interferon signaling suppresses expansion and mediates chemoresistance in human AML.** *Blood cancer discovery*
  Karigane, D., Fan, A. C., Nishimura, T., Kayamori, K., Nakauchi, Y., Köhnke, T., Rangavajhula, A., Ediriwickrema, A., Benard, B. A., Thomas, R., Zhao, F., Stafford, M., Suchy, et al
  2025

- **IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation**
  Castellan, F., Mustion, G., Wong, M., Johansson, K., Goldberg, S., Madanat, Y., Chandhok, N., Singh, A., Sallman, D., Churpek, J., Lachowiez, C., Yannucci, J., Fletcher, et al
  WILEY.2025: 5309-5310

- **Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.** *Nature reviews. Clinical oncology*
  Glaviano, A., Weisberg, E., Lam, H. Y., Tan, D. J., Innes, A. J., Ge, Y., Lai, C. E., Stock, W., Glytsou, C., Smit, L., Yoshida, T., Zhang, T. Y., Kennedy, et al
  2025

- **Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory acute myeloid leukemia.**
  Cho, W., Dutta, R., de Santiago, V., Cobarrubias, K., Choi, J., Inlow, E., Shaw, B., Cunanan, K., Charu, V., Ediriwickrema, A., Zhang, T., Mannis, G. N.
  LIPPINCOTT WILLIAMS & WILKINS.2025: TPS6582

- **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*
  Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al
  2025; 16 (1): 1824

- **The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a realworld study using large-scale electronic health record data.** *Haematologica*
  Schwede, M., Rodriguez, G., Kennedy, V. E., Henry, S., Wood, D., Mannis, G. N., Majeti, R., Chen, J. H., Bendavid, E., Zhang, T. Y.
  2025

- **MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis.** *NPJ precision oncology*
  Khanna, V., Eslami, G., Reyes, R., Diep, R., Fernandez-Pol, S., Stehr, H., Suarez, C. J., Pinto, H., Ford, J. M., Zhang, T. Y., Chen, C. T.
  2025; 9 (1): 34

- **Prognostic Significance of Low Copy Number FLT3 and NPM1 mrd As Detected By Ultra-Sensitive Next Generation Sequencing**
  Shannon, M. L., Zhang, T. Y., Muffly, L., Mannis, G. N.
  ELSEVIER.2024: 4330-4331

- **Prognostic Significance of CD123 Expression in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents**
  Tiu, B. C., Su, C. J., St Martin, E. C., Oak, J. S., Zhang, T. Y., Mannis, G. N.
  ELSEVIER.2024: 6104-6105

- **Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival**
  Gunaratne, R., Zhou, C., Tai, J. W., Kim, S., Tanaka, K., Rajaram, S., Carleton, M., Yin, R., Alkaitis, M., Schwede, M., Sworder, B. J., Khodadoust, M. S., Majeti, et al
  ELSEVIER.2024: 2955-2956

- **Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis** *BONE MARROW TRANSPLANTATION*
  Xie, Y., Kazakova, V., Weeks, L. D., Gerber, J. M., Tai, J., Zhang, T. Y., Lowsky, R., Wu, X., Yang, C., Patel, S. A.
  2024

- **p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.** *American journal of clinical pathology*
  Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., Zhang, T. Y., Gratzinger, D., Oak, J., Silva, O., Kurzer, J., Tan, B., Menke, et al
  2024

- **Natural history of clonal haematopoiesis seen in real-world haematology settings.** *British journal of haematology*
  Patel, S. A., Gerber, W. K., Zheng, R., Khanna, S., Hutchinson, L., Abel, G. A., Cerny, J., DaSilva, B. A., Zhang, T. Y., Ramanathan, M., Khedr, S., Selove, W., Woda, et al
  2024

- **Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the PostVenetoclax Era**
  St Martin, E. C., Schwede, M., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Zhang, T. Y., Mannis, G.
  AMER SOC HEMATOLOGY.2023

- **Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients**
  Moscvin, M., Schwede, M., Mannis, G., Zhang, T. Y.
  AMER SOC HEMATOLOGY.2023

- **Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis**
  Patel, S., Gerber, W. K., Zheng, R., Khanna, S., Hutchinson, L., Cerny, J., Dasilva, B., Zhang, T. Y., Khedr, S., Selove, W., Woda, B., Abel, G. A., Miron, et al
  AMER SOC HEMATOLOGY.2023

- **Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)**
  Gunaratne, R., Zhou, C., Tai, J. W., Schwede, M., Tanaka, K., Alkaitis, M., Yin, R., Sworder, B. J., Mannis, G., Majeti, R., Khodadoust, M. S., Kurtz, D. M., Zhang, et al
  AMER SOC HEMATOLOGY.2023

- **Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort**
  Cheung, E., Schumann, C., Zhang, T. Y., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Mannis, G.
  AMER SOC HEMATOLOGY.2023

- **Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia**
  Tai, J. W., Li, G., Tanaka, K., Gopakumar, J., Zhou, C., Linde, M., Villar-Prados, A., Rangavajhula, A. S., Trotman-Grant, A. C., Landberg, N., Fan, A. C., Mannis, G., Zhang, et al
  AMER SOC HEMATOLOGY.2023

- **Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations**
  Kuo, E., Santiago, V., Tanaka, K., Puram, V., Zhou, C., Tai, J. W., Mannis, G., Majeti, R., Zhang, T. Y.
  AMER SOC HEMATOLOGY.2023

- **The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data**
  Schwede, M., Rodriguez, G., Henry, S., Wood, D., Mannis, G., Majeti, R., Chen, J., Bendavid, E., Zhang, T. Y.
  AMER SOC HEMATOLOGY.2023

- **Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks**
  Sinha, R., Schwede, M., Ben Viggiano, Kuo, D., Henry, S., Wood, D., Mannis, G., Majeti, R., Chen, J., Zhang, T. Y.
  AMER SOC HEMATOLOGY.2023

- **Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)**
  Fleming, S., Roboz, G. J., Fathi, A. T., Zhang, T. Y., Wei, A., Carraway, H. E., Holes, L., Petrlik, E., Prebet, T., Menezes, D. L., Bluemmert, I., Sun, H., Ravandi, et al
  CIG MEDIA GROUP, LP.2023: S293

- **Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia**
  Fleming, S., Roboz, G. J., Fathi, A., Zhang, T., Wei, A., Carraway, H. E., Holes, L., Petrlik, E., Prebet, T., De Menezes, D., Bluemmert, I., Sun, H., Ravandi, et al
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia**
  Fleming, S., Roboz, G. J., Fathi, A., Zhang, T., Wei, A., Carraway, H. E., Holes, L., Petrlik, E., Prebet, T., de Menezes, D., Bluemmert, I., Sun, H., Ravandi, et al
  LIPPINCOTT WILLIAMS & WILKINS.2023: e19011

- **Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.** *Leukemia research*

Khanna, V., Azenkot, T., Liu, S. Q., Gilbert, J., Cheung, E., Lau, K., Pollyea, D. A., Traer, E., Jonas, B. A., Zhang, T. Y., Mannis, G. N.
2023; 131: 107331

- **The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough.** *Clinical lymphoma, myeloma & leukemia*
  St Martin, E. C., Zhang, T. Y., Mannis, G. N.
  2023

- **Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy.** *Cancer discovery*
  Linde, M. H., Fan, A. C., Kohnke, T., Trotman-Grant, A. C., Gurev, S. F., Phan, P., Zhao, F., Haddock, N. L., Nuno, K. A., Gars, E. J., Stafford, M., Marshall, P. L., Dove, et al
  2023

- **Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA**
  Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., Zhang, T. Y., Khodadoust, M. S., Miklos, D. B., Arai, S., Iberri, D., Liedtke, M., Sidana, et al
  AMER SOC HEMATOLOGY.2022: 1546-1548

- **Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis**
  Khanna, V., Azenkot, T., Liu, S., Gilbert, J., Cheung, E., Lau, K., Pollyea, D. A., Traer, E., Jonas, B. A., Zhang, T. Y., Mannis, G. N.
  AMER SOC HEMATOLOGY.2022: 3294-3296

- **Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients**
  Tan, I., Choi, J., Cunanan, K., Fronk, J., Zhang, T., Mannis, G. N., Ramchandran, K.
  CIG MEDIA GROUP, LP.2021: S279-S280

- **Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.** *Leukemia & lymphoma*
  Patel, S. A., Dalela, D., Fan, A. C., Lloyd, M. R., Zhang, T. Y.
  2021: 1-9

- **Reprogramming cancer into antigen presenting cells as a novel immunotherapy.**
  Linde, M. H., Gurev, S. F., Phan, P., Zhao, F., Gars, E. J., Stafford, M., Kohnke, T., Marshall, P. L., Fan, A. C., Dove, C. G., Linde, I. L., Miller, L. P., Majzner, et al
  AMER ASSOC CANCER RESEARCH.2021

- **Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.** *Leukemia & lymphoma*
  Ladha, A. n., Hui, G. n., Cheung, E. n., Berube, C. n., Coutre, S. E., Gotlib, J. n., Liedtke, M. n., Zhang, T. Y., Muffly, L. n., Mannis, G. N.
  2021: 1–6

- **Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)**
  Tan, I., Schwede, M., Phan, P., Yin, R., Zhang, T. Y., Mannis, G. N.
  2021

- **Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia.** *Leukemia & lymphoma*
  Patel, S. A., Lloyd, M. R., Cerny, J., Shi, Q., Simin, K., Ediriwickrema, A., Hutchinson, L., Miron, P. M., Higgins, A. W., Ramanathan, M., Gerber, J. M.
  2021: 1-13

- **Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.** *Journal of medical case reports*
  Dutta, R. n., Miao, S. Y., Phan, P. n., Fernandez-Pol, S. n., Shiraz, P. n., Ho, D. n., Mannis, G. N., Zhang, T. Y.
  2021; 15 (1): 170

- **Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML.** *Cell stem cell*
  Zhang, T. Y., Majeti, R.
  2020; 27 (5): 693–95

- **Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney.** *Leukemia*

Wong, R. L., Ketcham, M., Irwin, T., Akilesh, S., Zhang, T. Y., Reyes, J. D., Edlefsen, K., Jalikis, F., Becker, P. S.
2020

- **IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia.** *Science translational medicine*
  Zhang, T. Y., Dutta, R., Benard, B., Zhao, F., Yin, R., Majeti, R.
  2020; 12 (538)

- **Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.** *The Journal of clinical investigation*
  Dutta, R. n., Zhang, T. Y., Köhnke, T. n., Thomas, D. n., Linde, M. n., Gars, E. n., Stafford, M. n., Kaur, S. n., Nakauchi, Y. n., Yin, R. n., Azizi, A. n., Narla, A. n., Majeti, et al
  2020

- **Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.** *Leukemia & lymphoma*
  Azizi, A. n., Ediriwickrema, A. n., Dutta, R. n., Patel, S. A., Shomali, W. n., Medeiros, B. n., Iberri, D. n., Gotlib, J. n., Mannis, G. n., Greenberg, P. n., Majeti, R. n., Zhang, T. n.
  2020: 1–8

- **Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.** *American journal of hematology*
  Jeng, M. Y., Dutta, R. n., Tan, I. T., Zhang, T. Y., Mannis, G. N.
  2020

- **Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2**
  Dutta, R., Zhang, T. Y., Koehnke, T., Thomas, D., Gars, E., Stafford, M., Nakauchi, Y., Kaur, S., Yin, R., Narla, A., Majeti, R.
  AMER SOC HEMATOLOGY.2019

- **Human Acute Myeloid Leukemia Inhibits Normal Erythroid Differentiation through the Paracrine Effects of IL-6**
  Zhang, T. Y., Dutta, R., Zhao, F., Majeti, R.
  AMER SOC HEMATOLOGY.2018

- **beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia** *LEUKEMIA*
  Eiring, A. M., Khorashad, J. S., Anderson, D. J., Yu, F., Redwine, H. M., Mason, C. C., Reynolds, K. R., Clair, P. M., Gantz, K. C., Zhang, T. Y., Pomicter, A. D., Kraft, I. L., Bowler, et al
  2015; 29 (12): 2328–37

- **Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia** *LEUKEMIA*
  Eiring, A. M., Page, B. G., Kraft, I. L., Mason, C. C., Vellore, N. A., Resetca, D., Zabriskie, M. S., Zhang, T. Y., Khorashad, J. S., Engar, A. J., Reynolds, K. R., Anderson, D. J., Senina, et al
  2015; 29 (3): 586–97

- **KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors** *CANCER RESEARCH*
  Corbin, A. S., O'Hare, T., Gu, Z., Kraft, I. L., Eiring, A. M., Khorashad, J. S., Pomicter, A. D., Zhang, T. Y., Eide, C. A., Manley, P. W., Cortes, J. E., Druker, B. J., Deininger, et al
  2013; 73 (18): 5775–86

- **Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice** *JOURNAL OF CLINICAL INVESTIGATION*
  De Domenico, I., Zhang, T. Y., Koening, C. L., Branch, R. W., London, N., Lo, E., Daynes, R. A., Kushner, J. P., Li, D., Ward, D. M., Kaplan, J.
  2010; 120 (7): 2395–2405

- **Macrophages from 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice exhibit an increased sensitivity to lipopolysaccharide stimulation due to TGF-beta-Mediated up-regulation of SHIP1 expression** *JOURNAL OF IMMUNOLOGY*
  Zhang, T. Y., Daynes, R. A.
  2007; 179 (9): 6325–35

- **Glucocorticoid conditioning of myeloid progenitors enhances TLR4 signaling via negative regulation of the phosphatidylinositol 3-kinase-Akt pathway** *JOURNAL OF IMMUNOLOGY*
  Zhang, T. Y., Daynes, R. A.
  2007; 178 (4): 2517–26

- **The expression of 11 beta-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities** *JOURNAL OF IMMUNOLOGY*
  Zhang, T. Y., Ding, X. H., Daynes, R. A.
  2005; 174 (2): 879–89

- **Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation** *JOURNAL OF IMMUNOLOGY*
  Jones, D. C., Ding, X. H., Zhang, T. Y., Daynes, R. A.
  2003; 171 (1): 196–203